68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy

Launched by CENTRE DE RECHERCHE DU CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE · Jan 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see if certain patients with upper gastrointestinal (GI) cancers, such as cancers of the esophagus, stomach, bile ducts, or pancreas, might be suitable for a special treatment called endoradiotherapy (ERT). ERT uses targeted radiation to treat cancer cells while trying to protect healthy tissue, which can lead to fewer side effects than traditional treatments. The main goal of this study is to use a type of imaging called 68Ga-PSMA PET scans to determine if patients with active cancer are eligible for this promising therapy.

To be eligible for this trial, participants need to be at least 18 years old and have a confirmed diagnosis of adenocarcinoma, which is a specific type of cancer, shown by a recent CT scan. They should have at least one active cancer lesion that has not been fully treated or that has shown progression. Participants must also be able to give informed consent and undergo the required imaging within two months of their CT scan. The trial is currently recruiting and welcomes all genders, but individuals with other active cancers, certain health conditions, or who are pregnant cannot participate. If you decide to join, you will undergo imaging tests and may gain access to new treatment options that could help manage your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years and older
• • Active cancer of the type adenocarcinoma (of the esophagus, of the stomach, of the bile ducts, or of the pancreas) documented by a CT scan performed within the last 8 weeks at the time of recruitment.
• • An active cancer is defined as at least one lesion identified as stable or progressive neoplastic on CT imaging.
• • A lesion treated with local therapy (e.g., external radiotherapy, cryoablation, radiofrequency ablation, resection) is not counted for inclusion criteria if this is done between the CT scan and the 68Ga-PSMA PET imaging. A lesion treated prior to the last CT scan may be considered eligible if progression is documented at the last CT scan.
• • Able to provide free and informed consent.
• • Feasibility to perform 68Ga-PSMA PET within 2 months of the CT scan that was used for inclusion.
• Exclusion Criteria:
• • Other active cancer (non-metastatic non-melanoma skin cancer excluded). Cancer in remission for at least 3 years will not be considered active.
• • ECOG \> 3.
• • Pregnant woman.
• • Unable to follow study rules.